Alpha Teknova, Inc.

Alpha Teknova, Inc. (ticker: TKNO) is an NASDAQ-listed in vitro & in vivo diagnostic substances company. DredgeCap's structured extraction of TKNO's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. TKNO reported $11.08M in revenue and -$4.55M for the period ending 2026-03-31, with operating cash flow of -$3.36M. Cash and equivalents stood at $4.31M (up 27.5% year-over-year). Total assets of $98.66M exceed total liabilities of $33.73M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

TKNO Cash Runway

Months-of-runway analysis for TKNO, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on TKNO

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.